Early and late pace-maker implantation after transcatheter and surgical aortic valve replacement.
SAVR
TAVI
TAVR
aortic valve replacement
pacemaker
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
06
07
2020
received:
13
06
2020
accepted:
19
07
2020
pubmed:
9
8
2020
medline:
25
9
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
Conduction defects requiring permanent pacemaker (PPM) implantation are frequent complications occurring after surgical (SAVR) and transcatheter aortic valve replacement (TAVR). Patients who underwent TAVR or SAVR with a bioprosthesis from the nationwide FinnValve registry were the subjects of this study. Patients with prior PPM, who received a sutureless prosthesis, or required cardiac resynchronization therapy or implantable cardioverter defibrillator were excluded from this analysis. Four thousand and ten patients underwent SAVR and 1,897 underwent TAVR. TAVR had an increased risk of PPM implantation at 30-day (10.1% vs. 3.5%, unadjusted OR 3.11, 95%CI 2.56-3.87) and 5-year (15.7% vs. 8.6%, unadjusted SHR, 2.12, 95%CI 1.81-2.48) compared to SAVR. PPM implantation within 30 days from the index procedure did not increase the risk of 5-year mortality after either SAVR or TAVR. Among 1,042 propensity score matched pairs, TAVR had an increased risk of PPM implantation at 30-day (9.9% vs. 4.7%, p < .0001) and 5-year (14.7% vs. 11.4%, p = .001), but late (>30 days) PPM implantation at 5-year (4.7% vs. 6.9% SHR 0.72, 95%CI 0.47-1.10) was comparable to SAVR. The types of prosthesis had an impact on 30-day PPM implantation after TAVR, but not on late (>30 days) PPM implantation. Although the risk of 30-day PPM implantation is higher after TAVR compared to SAVR, late (>30 days) PPM implantation was comparable with these treatment methods. PPM implantation within 30 days did not affect late survival.
Sections du résumé
BACKGROUND
Conduction defects requiring permanent pacemaker (PPM) implantation are frequent complications occurring after surgical (SAVR) and transcatheter aortic valve replacement (TAVR).
METHODS
Patients who underwent TAVR or SAVR with a bioprosthesis from the nationwide FinnValve registry were the subjects of this study. Patients with prior PPM, who received a sutureless prosthesis, or required cardiac resynchronization therapy or implantable cardioverter defibrillator were excluded from this analysis.
RESULTS
Four thousand and ten patients underwent SAVR and 1,897 underwent TAVR. TAVR had an increased risk of PPM implantation at 30-day (10.1% vs. 3.5%, unadjusted OR 3.11, 95%CI 2.56-3.87) and 5-year (15.7% vs. 8.6%, unadjusted SHR, 2.12, 95%CI 1.81-2.48) compared to SAVR. PPM implantation within 30 days from the index procedure did not increase the risk of 5-year mortality after either SAVR or TAVR. Among 1,042 propensity score matched pairs, TAVR had an increased risk of PPM implantation at 30-day (9.9% vs. 4.7%, p < .0001) and 5-year (14.7% vs. 11.4%, p = .001), but late (>30 days) PPM implantation at 5-year (4.7% vs. 6.9% SHR 0.72, 95%CI 0.47-1.10) was comparable to SAVR. The types of prosthesis had an impact on 30-day PPM implantation after TAVR, but not on late (>30 days) PPM implantation.
CONCLUSIONS
Although the risk of 30-day PPM implantation is higher after TAVR compared to SAVR, late (>30 days) PPM implantation was comparable with these treatment methods. PPM implantation within 30 days did not affect late survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E560-E568Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715. https://doi.org/10.1056/NEJMoa1816885.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. https://doi.org/10.1056/NEJMoa1814052.
Levack MM, Kapadia SR, Soltesz EG, et al. Prevalence of and risk factors for permanent pacemaker implantation after aortic valve replacement. Ann Thorac Surg. 2019;108:700-707. https://doi.org/10.1016/j.athoracsur.2019.03.056.
Mäkikallio T, Jalava MP, Husso A, et al. Ten-year experience with transcatheter and surgical aortic valve replacement in Finland. Ann Med. 2019;51:270-279. https://doi.org/10.1080/07853890.2019.1614657.
van Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J. 2018;39:2003-2013. https://doi.org/10.1093/eurheartj/ehx785.
Biancari F, Martin M, Bordin G, et al. Basic data from 176 studies on the immediate outcome after aortic valve replacement with or without coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2014;28:1251-1256. https://doi.org/10.1053/j.jvca.2013.07.020.
Leyva F, Qiu T, McNulty D, Evison F, Marshall H, Gasparini M. Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm. 2017;14:529-534. https://doi.org/10.1016/j.hrthm.2016.11.029.
Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60:1743-1752. https://doi.org/10.1016/j.jacc.2012.07.035.
Piazza N, Nuis RJ, Tzikas A, et al. Persistent conduction abnormalities and requirements for pacemaking six months after transcatheter aortic valve implantation. EuroIntervention. 2010;6:475-484. https://doi.org/10.4244/EIJ30V6I4A80.
Barbanti M, Tamburino C, D'Errigo P, et al. Five-year outcomes of transfemoral transcatheter aortic valve replacement or surgical aortic valve replacement in a real world population. Circ Cardiovasc Interv. 2019;12:e007825. https://doi.org/10.1161/CIRCINTERVENTIONS.119.007825.
Bagur R, Manazzoni JM, Dumont É, et al. Permanent pacemaker implantation following isolated aortic valve replacement in a large cohort of elderly patients with severe aortic stenosis. Heart. 2011;97:1687-1694. https://doi.org/10.1136/heartjnl-2011-300308.
Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT registry. JACC Cardiovasc Interv. 2016;9:2189-2199. https://doi.org/10.1016/j.jcin.2016.07.026.
Siontis GC, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129-140. https://doi.org/10.1016/j.jacc.2014.04.033.
Nuis RJ, Van Mieghem NM, Tzikas A, et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2011;77:881-889.
Nuis RJ, Van Mieghem NM, Tzikas A, et al. Impact of new-onset persistent left bundle branch block on late clinical outcomes in patients undergoing transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv. 2014;7:128-136. https://doi.org/10.1002/ccd.22874.
Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients uUndergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2016;9:e003635. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003635.
Buellesfeld L, Stortecky S, Heg D, et al. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;60:493-501. https://doi.org/10.1016/j.jacc.2012.03.054.
Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734-745. https://doi.org/10.1093/ejcts/ezs468.
Society of Thoracic Surgeons. Online STS Risk Calculator. http://riskcalc.sts.org/stswebriskcalc/ accessed June 2020.
Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hébert R, Hogan DB. A brief clinical instrument to classify frailty in elderly people. Lancet. 1999;353:205-206. https://doi.org/10.1016/S0140-6736(98)04402-X.
Jilaihawi H, Zhao Z, Du R, Staniloae C, et al. Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1796-1807. https://doi.org/10.1016/j.jcin.2019.05.056.
Bagur R, Rodés-Cabau J, Gurvitch R, et al. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv. 2012;5:540-551. https://doi.org/10.1016/j.jcin.2012.03.004.
Ream K, Sandhu A, Valle J, et al. Ambulatory rhythm monitoring to detect late high-grade atrioventricular block following transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;73:2538-2547. https://doi.org/10.1016/j.jacc.2019.02.068.
Nombela-Franco L, Rodés-Cabau J, DeLarochellière R, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv. 2012;5:499-512. https://doi.org/10.1016/j.jcin.2012.02.010.
Oh JK, Little SH, Abdelmoneim SS, et al. Regression of paravalvular aortic regurgitation and eemodeling of self-expanding transcatheter aortic valve: an observation from the CoreValve U.S. pivotal trial. JACC Cardiovasc Imaging. 2015;8:1364-1375. https://doi.org/10.1016/j.jcmg.2015.07.012.
Mehaffey JH, Haywood NS, Hawkins RB, et al. Need for permanent pacemaker after surgical aortic valve replacement reduces long-term survival. Ann Thorac Surg. 2018;106:460-465. https://doi.org/10.1016/j.athoracsur.2018.02.041.
Tarantini G, Fabris T. Transcatheter aortic valve replacement without previous conduction disturbances: the importance of preventing iatrogenic pacemaker implantation. Catheter Cardiovasc Interv. 2020;95:991-992. https://doi.org/10.1002/ccd.28880.
Van Mieghem NM, Head SJ, de Jong W, et al. Persistent annual permanent pacemaker implantation rate after surgical aortic valve replacement in patients with severe aortic stenosis. Ann Thorac Surg. 2012;94:1143-1149. https://doi.org/10.1016/j.athoracsur.2012.04.038.
Barrett TW, Abraham RL, Jenkins CA, Russ S, Storrow AB, Darbar D. Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation. Am J Cardiol. 2012;110:1315-1321. https://doi.org/10.1016/j.amjcard.2012.06.037.